149 related articles for article (PubMed ID: 29493783)
1. Precious GEMMs: emergence of faithful models for ovarian cancer research.
Stuckelberger S; Drapkin R
J Pathol; 2018 Jun; 245(2):129-131. PubMed ID: 29493783
[TBL] [Abstract][Full Text] [Related]
2. High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.
Zhai Y; Wu R; Kuick R; Sessine MS; Schulman S; Green M; Fearon ER; Cho KR
J Pathol; 2017 Sep; 243(1):16-25. PubMed ID: 28608929
[TBL] [Abstract][Full Text] [Related]
3. Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.
Wu R; Zhai Y; Kuick R; Karnezis AN; Garcia P; Naseem A; Hu TC; Fearon ER; Cho KR
J Pathol; 2016 Nov; 240(3):341-351. PubMed ID: 27538791
[TBL] [Abstract][Full Text] [Related]
4. Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
Maru Y; Tanaka N; Tatsumi Y; Nakamura Y; Yao R; Noda T; Itami M; Hippo Y
J Pathol; 2021 Oct; 255(2):177-189. PubMed ID: 34184756
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. Tubal origin of ovarian cancer - the double-edged sword of haemoglobin.
Lin SF; Gerry E; Shih IM
J Pathol; 2017 May; 242(1):3-6. PubMed ID: 28054715
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
[TBL] [Abstract][Full Text] [Related]
8. MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; Long DT; Spruill L; Romeo MJ; Helke KL; Delaney JR
bioRxiv; 2024 Jan; ():. PubMed ID: 38352443
[TBL] [Abstract][Full Text] [Related]
9. Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches.
Zakarya R; Howell VM; Colvin EK
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32645943
[TBL] [Abstract][Full Text] [Related]
10. Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
Hou X; Zhai Y; Hu K; Liu CJ; Udager A; Pearce CL; Fearon ER; Cho KR
Gynecol Oncol; 2022 Jun; 165(3):552-559. PubMed ID: 35414426
[TBL] [Abstract][Full Text] [Related]
11. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered mouse models for epithelial ovarian cancer: are we there yet?
Howell VM
Semin Cell Dev Biol; 2014 Mar; 27():106-17. PubMed ID: 24685617
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
[TBL] [Abstract][Full Text] [Related]
14. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
15. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
16. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S; Iyer S; Ran H; Dolgalev I; Gu S; Wei W; Foster CJR; Loomis CA; Olvera N; Dao F; Levine DA; Weinberg RA; Neel BG
Cancer Discov; 2021 Feb; 11(2):362-383. PubMed ID: 33158842
[TBL] [Abstract][Full Text] [Related]
17.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
18. Role of Fallopian Tubes in the Development of Ovarian Cancer.
Corzo C; Iniesta MD; Patrono MG; Lu KH; Ramirez PT
J Minim Invasive Gynecol; 2017 Feb; 24(2):230-234. PubMed ID: 28007588
[TBL] [Abstract][Full Text] [Related]
19. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Kim J; Coffey DM; Ma L; Matzuk MM
Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
[TBL] [Abstract][Full Text] [Related]
20. Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
Chen L; Zhai Y; Wang Y; Fearon ER; Núñez G; Inohara N; Cho KR
Cancer Res; 2021 Jun; 81(12):3309-3318. PubMed ID: 33863776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]